---
title: "Polaryx Therapeutics, Inc. (PLYX.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLYX.US/overview.md"
symbol: "PLYX.US"
name: "Polaryx Therapeutics, Inc."
parent: "https://longbridge.com/en/quote/PLYX.US.md"
datetime: "2026-04-15T21:21:54.411Z"
locales:
  - [en](https://longbridge.com/en/quote/PLYX.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLYX.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLYX.US/overview.md)
---

# Polaryx Therapeutics, Inc. (PLYX.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Address | South Tower, 140 E Ridgewood Avenue, Suite 415, Paramus, New Jersey, United States |
| Website | [olaryx.com](https://olaryx.com) |

## Company Profile

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

## Key Executives

| Name | Title |
|------|-------|
| Alex Yang | CEO & Chair of Board |
| G. Michael Landis | CFO & Director |
| Andrew John O | Chief Investment Officer |
| Lisa L. Bollinger | Chief Medical Officer |
| Shrijay Vijayan | Chief Scientific & Business Development Officer |
| Francis A. Braun | Independent Director |
| Mitchel S. Berger | Independent Director |
| Charles S. Ryan | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Mstone Partners Hong Kong Limited | 47.43% | 2026-01-29 |
| Gershon Koh | 11.67% | 2026-01-12 |
| Rush University Medical Center | 8.04% | 2026-01-12 |
| Jae-Hoon Kim | 5.35% | 2026-01-12 |
| Hahn-Jun Lee | 4.96% | 2026-01-12 |
| Laputa Cooperative | 4.36% | 2026-01-12 |
| Healutyx, Co., Ltd | 3.49% | 2026-01-12 |
| Jung Jun Lee | 2.35% | 2026-01-12 |
| Sangcheon Mun | 2.11% | 2026-01-12 |
| Meridian Holdings Co., Ltd. | 1.06% | 2026-01-12 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**